Close Menu
Global News HQ
    What's Hot

    Exploring the No Tipping Trend: What It Means for Diners and Workers

    June 29, 2025

    Can China’s MiniMax-M1 AI Topple US Rivals? We Put It to the Test – Decrypt

    June 29, 2025

    The Future of Social Security Just Went From Bad to Worse. Here’s What Seniors Can Expect Next. | The Motley Fool

    June 29, 2025
    Recent Posts
    • Exploring the No Tipping Trend: What It Means for Diners and Workers
    • Can China’s MiniMax-M1 AI Topple US Rivals? We Put It to the Test – Decrypt
    • The Future of Social Security Just Went From Bad to Worse. Here’s What Seniors Can Expect Next. | The Motley Fool
    • Unsuspecting Elderly Widow Loses $281K in a Romance Scam: The Dark Side of Crypto
    • OpenAI Loses 4 Key Researchers to Meta
    Facebook X (Twitter) Instagram YouTube TikTok
    Trending
    • Exploring the No Tipping Trend: What It Means for Diners and Workers
    • Can China’s MiniMax-M1 AI Topple US Rivals? We Put It to the Test – Decrypt
    • The Future of Social Security Just Went From Bad to Worse. Here’s What Seniors Can Expect Next. | The Motley Fool
    • Unsuspecting Elderly Widow Loses $281K in a Romance Scam: The Dark Side of Crypto
    • OpenAI Loses 4 Key Researchers to Meta
    • The Distillers Advocating for Radical Transparency in Whiskey Making
    • Tesla says it delivered its first car autonomously from factory to customer
    • How To Keep Outdoor Wood Beautiful Year-Round: Best Sealers for the Job
    Global News HQ
    • Technology & Gadgets
    • Travel & Tourism (Luxury)
    • Health & Wellness (Specialized)
    • Home Improvement & Remodeling
    • Luxury Goods & Services
    • Home
    • Finance & Investment
    • Insurance
    • Legal
    • Real Estate
    • More
      • Cryptocurrency & Blockchain
      • E-commerce & Retail
      • Business & Entrepreneurship
      • Automotive (Car Deals & Maintenance)
    Global News HQ
    Home - Luxury Goods & Services - AbbVie Lifts Profit Guidance, Cosmetic Treatments Revenue Lags
    Luxury Goods & Services

    AbbVie Lifts Profit Guidance, Cosmetic Treatments Revenue Lags

    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    AbbVie Lifts Profit Guidance, Cosmetic Treatments Revenue Lags
    Share
    Facebook Twitter LinkedIn Pinterest Email



    AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in trade policy.

    The drugmaker raised its 2025 adjusted earnings by 10 cents to a range of $12.09 to $12.29 a share. That “does not reflect any trade policy shifts, including pharmaceutical sector tariffs, that could impact AbbVie’s business,” according to a statement.

    The company said it expects a $30 million charge from tariffs that are already in place, mostly related to its aesthetics business.

    Investors have been focused on how companies are navigating existing tariffs and the potential for new levies to be imposed on pharmaceutical imports to the US. Larger competitors like Johnson & Johnson and Merck & Co. already warned tariffs will cost them hundreds of millions of dollars.

    Potential tariff impacts would be “in line” with AbbVie’s peers, chief executive officer Rob Michael said on a call with investors. The company plans to invest $10 billion in the US over the next decade, he said.

    AbbVie has looked to Skyrizi and Rinvoq — a pair of newer autoimmune medicines — to make up for fading revenue from its aging blockbuster Humira. That strategy is showing signs of working: Both drugs beat estimates in the first quarter, with combined sales of $5.14 billion.

    That helped the company surpass quarterly revenue expectations. AbbVie recorded $13.34 billion in overall sales, beating analyst estimates. Adjusted earnings for the quarter were $2.46 a share, above Wall Street’s expectations.

    “Overall, today’s results highlight the continued strong momentum of the company’s core franchise, particularly in immunology,” JPMorgan analyst Chris Schott said in a note.

    Shares in AbbVie jumped as much as 4.6 percent when markets opened in New York, before paring gains. The North Chicago-based company rose 1.5 percent this year through Thursday, outperforming a roughly 7 percent drop in the S&P 500 Index.

    AbbVie’s aesthetics business, which includes anti-wrinkle treatments like Botox, missed Wall Street’s estimates in the period. The segment is particularly sensitive to pullbacks in consumer spending because patients typically pay out of pocket. Botox will also be susceptible to potential tariffs on European countries since it’s made at a plant in Ireland.

    The company is also seeking approval from the US Food and Drug Administration for a new, faster-acting wrinkle treatment that only lasts a few weeks. It’s meant to be an option for patients who want the effects of Botox, but cite fears of “looking unnatural,” AbbVie said. The treatment is expected to hit the market next year, Michael said on the call.

    Recent deals in obesity and a fast-growing area of cancer drug development called “molecular glue” may help replenish AbbVie’s future pipeline after a next-generation schizophrenia drug failed two mid-stage studies last year. The company is analysing the data from those trials to determine next steps.

    AbbVie’s full year guidance includes impacts from ongoing research and development.

    By Madison Muller

    Learn more:

    ‘Filler Fatigue’ Is Setting In

    Growing concern around their long-term effects and fears of poor placement or technique are turning some consumers off from injectable fillers. There’s a new category of treatments that might fit the bill instead: biostimulators.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleStagflation Warning Signs: What Real Estate Investors Need to Know
    Next Article Public Space Has Become Earbud Space

    Related Posts

    The Distillers Advocating for Radical Transparency in Whiskey Making

    June 29, 2025

    Ralph Pucci Marks 70 Years with ‘PURE’ at Château La Coste – Elite Traveler

    June 28, 2025

    Kenzo Spring 2026 Menswear Collection

    June 28, 2025

    Baglietto and Meyer Davis Just Teamed up on a Sleek 183-Foot Superyacht

    June 28, 2025
    Leave A Reply Cancel Reply

    ads
    Don't Miss
    Business & Entrepreneurship
    8 Mins Read

    Exploring the No Tipping Trend: What It Means for Diners and Workers

    Key TakeawaysEmergence of No Tipping: The no tipping trend is gaining traction as more businesses…

    Can China’s MiniMax-M1 AI Topple US Rivals? We Put It to the Test – Decrypt

    June 29, 2025

    The Future of Social Security Just Went From Bad to Worse. Here’s What Seniors Can Expect Next. | The Motley Fool

    June 29, 2025

    Unsuspecting Elderly Widow Loses $281K in a Romance Scam: The Dark Side of Crypto

    June 29, 2025
    Top
    Business & Entrepreneurship
    8 Mins Read

    Exploring the No Tipping Trend: What It Means for Diners and Workers

    Key TakeawaysEmergence of No Tipping: The no tipping trend is gaining traction as more businesses…

    Can China’s MiniMax-M1 AI Topple US Rivals? We Put It to the Test – Decrypt

    June 29, 2025

    The Future of Social Security Just Went From Bad to Worse. Here’s What Seniors Can Expect Next. | The Motley Fool

    June 29, 2025
    Our Picks
    Business & Entrepreneurship
    8 Mins Read

    Exploring the No Tipping Trend: What It Means for Diners and Workers

    Key TakeawaysEmergence of No Tipping: The no tipping trend is gaining traction as more businesses…

    Cryptocurrency & Blockchain
    10 Mins Read

    Can China’s MiniMax-M1 AI Topple US Rivals? We Put It to the Test – Decrypt

    In brief MiniMax-M1 excels at coding and agent tasks, but creative writers will want to…

    Pages
    • About Us
    • Contact Us
    • Disclaimer
    • Homepage
    • Privacy Policy
    Facebook X (Twitter) Instagram YouTube TikTok
    • Home
    © 2025 Global News HQ .

    Type above and press Enter to search. Press Esc to cancel.

    Go to mobile version